Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Sales (2016 - 2025)

Historic Return on Sales for Ligand Pharmaceuticals (LGND) over the last 14 years, with Q3 2025 value amounting to 1.02%.

  • Ligand Pharmaceuticals' Return on Sales changed N/A to 1.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19%, marking a year-over-year change of. This contributed to the annual value of 0.02% for FY2024, which is 100.0% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Return on Sales stood at 1.02% for Q3 2025.
  • Ligand Pharmaceuticals' Return on Sales' 5-year high stood at 1.02% during Q3 2025, with a 5-year trough of 0.94% in Q1 2025.
  • Its 5-year average for Return on Sales is 0.1%, with a median of 0.07% in 2021.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Return on Sales soared by 6300bps in 2021, and later plummeted by -7100bps in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Return on Sales (Quarter) stood at 0.04% in 2021, then crashed by -49bps to 0.06% in 2022, then soared by 78bps to 0.01% in 2023, then plummeted by -5627bps to 0.73% in 2024, then skyrocketed by 240bps to 1.02% in 2025.
  • Its Return on Sales was 1.02% in Q3 2025, compared to 0.1% in Q2 2025 and 0.94% in Q1 2025.